These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38682738)

  • 1. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
    Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE
    Future Oncol; 2024; 20(21):1495-1503. PubMed ID: 38682738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
    Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE
    Future Oncol; 2024 May; ():1-19. PubMed ID: 38861289
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma.
    Kawashima A; Kanazawa T; Kidani Y; Yoshida T; Hirata M; Nishida K; Nojima S; Yamamoto Y; Kato T; Hatano K; Ujike T; Nagahara A; Fujita K; Morimoto-Okazawa A; Iwahori K; Uemura M; Imamura R; Ohkura N; Morii E; Sakaguchi S; Wada H; Nonomura N
    Sci Rep; 2020 Apr; 10(1):6220. PubMed ID: 32277125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.
    Rebuzzi SE; Brunelli M; Galuppini F; Vellone VG; Signori A; Catalano F; Damassi A; Gaggero G; Rescigno P; Maruzzo M; Merler S; Vignani F; Cavo A; Basso U; Milella M; Panepinto O; Mencoboni M; Sbaraglia M; Dei Tos AP; Murianni V; Cremante M; Llaja Obispo MA; Maffezzoli M; Banna GL; Buti S; Fornarini G
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.
    Sammarco E; Rossetti M; Salfi A; Bonato A; Viacava P; Masi G; Galli L; Faviana P
    Med Oncol; 2024 May; 41(6):150. PubMed ID: 38740647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
    Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
    Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
    Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
    Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
    Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Claps M; Chiellino S; Zampiva I; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Cerbone L; Antonuzzo L; Roviello G
    Front Immunol; 2024; 15():1361010. PubMed ID: 39034992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
    Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
    Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
    Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
    J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.